Calendario›ESLA›EB103 · STARLIGHT-1

EB103 · STARLIGHT-1

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ensayo de Estrella Immunopharma, Inc. en B-Cell Non-Hodgkin's Lymphoma (NHL) · Lymphoma, Non-Hodgkins · Lymphomas Non-Hodgkin's B-Cell · Non-Hodgkin Lymphoma · Non-Hodgkin's Lymphoma · Large B-Cell Lymphoma · Lymphoma, Non-Hodgkin's, Adult · Lymphoma · Refractory Non-Hodgkin Lymphoma · Relapsed Non-Hodgkin Lymphoma · Lymphoma, Non-Hodgkin · HIV Associated Lymphoma · CNS Lymphoma · High-grade B-cell Lymphoma · Refractory B-Cell Non-Hodgkin Lymphoma (del registro, en inglés).

Más ensayos de: Linfoma no Hodgkin · Linfoma.

Fase

Fase 1/2

Estado

Reclutando pacientes

Participantes

27

previstos

Centros

5

Fin del objetivo primario

jul 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, de un solo grupo, abierto. Comenzó en jun 2024.

Qué mide

To assess the safety and tolerability of EB103. (Up to 2 years (active assessment period); additional long-term follow-up (LTFU) up to 15 years) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis is an open-label, multi-center, Phase 1/2 clinical trial evaluating the safety and effectiveness of EB103 in R/R B-cell NHL patients with the highest unmet medical needs, such as Human Immunodeficiency Virus (HIV)-associated lymphoma, primary and secondary central nervous system (CNS) lymphoma, and a wide range of high-grade B-cell lymphomas (HGBLs), as well as R/R large B-cell lymphoma (LBCL) patients ineligible for autologous transplant.

Ficha completa en ClinicalTrials.gov (NCT06343311), actualizada en sep 2026.